Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 7/20 | 0.54 |
| ▸ | FSHR | P23945 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026187 | 0.94 | LHCGR (0.52) | LHCGRFSHRTSHRBRAFJAK3 | |
| SCHEMBL5028895 | 0.92 | LHCGR (0.54) | LHCGRFSHRTSHRBRAFJAK3 | |
| SCHEMBL5030959 | 0.90 | LHCGR (0.51) | LHCGRFSHRTSHRBRAFMEN1 | |
| SCHEMBL5026958 | 0.89 | LHCGR (0.51) | LHCGRFSHRTSHRBRAFMEN1 | |
| SCHEMBL5024685 | 0.88 | BRAF (0.58) | BRAFJAK3MAPT | |
| SCHEMBL5028843 | 0.87 | LHCGR (0.72) | LHCGRFSHRTSHRBRAF | |
| SCHEMBL6220667 | 0.87 | LHCGR (0.53) | LHCGRFSHRTSHRBRAFMEN1 | |
| SCHEMBL4426367 | 0.87 | LHCGR (0.55) | LHCGRFSHRTSHRBRAFCHRM4 | |
| SCHEMBL6224284 | 0.87 | LHCGR (0.50) | LHCGRFSHRTSHRBRAFMEN1 | |
| SCHEMBL5026098 | 0.85 | LHCGR (0.62) | LHCGRFSHRTSHRBRAFCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | LHCGR 3/4885FSHR 1/4885TSHR 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.